Targeting the cancer kinome through polypharmacology (original) (raw)

• Akritopoulou-Zanze, I. & Hajduk, P. J. Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors. Drug Discov. Today 14, 291–297 (2009).
  Article CAS PubMed Google Scholar
• Parsons, D. W. et al. Colorectal cancer: mutations in a signalling pathway. Nature 436, 792 (2005).
  Article CAS PubMed Google Scholar
• Wood, L. D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108–1113 (2007).
  Article CAS PubMed Google Scholar
• Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268–274 (2006).
  Article CAS PubMed Google Scholar
• Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).
  Article CAS PubMed Google Scholar
• Heinrich, M. C. et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342–4349 (2003).
  Article CAS PubMed Google Scholar
• Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408–2417 (2006).
  Article CAS PubMed Google Scholar
• Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449–456 (2008).
  Article CAS PubMed Google Scholar
• Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007).
  Article CAS PubMed Google Scholar
• Yang, J. C. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427–434 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).
  Article CAS PubMed Google Scholar
• Shepherd, F. A. et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123–132 (2005).
  Article CAS PubMed Google Scholar
• Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542–2550 (2006).
  Article CAS PubMed Google Scholar
• Geyer, C. E. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733–2743 (2006).
  Article CAS PubMed Google Scholar
• Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666–2676 (2007).
  Article CAS PubMed Google Scholar
• Jonker, D. J. et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357, 2040–2048 (2007).
  Article CAS PubMed Google Scholar
• Moore, M. J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960–1966 (2007).
  Article CAS PubMed Google Scholar
• Ciardiello, F. & Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358, 1160–1174 (2008).
  Article CAS PubMed Google Scholar
• Hudis, C. A. Trastuzumab — mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39–51 (2007).
  Article CAS Google Scholar
• Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757–1765 (2008).
  Article CAS PubMed Google Scholar
• Pao, W. et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, 17 (2005).
  Article CAS Google Scholar
• Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876–880 (2001).
  Article CAS PubMed Google Scholar
• Tamborini, E. et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127, 294–299 (2004).
  Article CAS PubMed Google Scholar
• Cools, J. et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348, 1201–14 (2003).
  Article CAS PubMed Google Scholar
• Chen, L. L. et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 64, 5913–5919 (2004).
  Article CAS PubMed Google Scholar
• Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, 73 (2005).
  Article CAS Google Scholar
• Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039–1043 (2007).
  Article CAS PubMed Google Scholar
• Sergina, N. V. et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445, 437–441 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Stommel, J. M. et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287–290 (2007).
  Article CAS PubMed Google Scholar
• Mellinghoff, I. K. et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012–2024 (2005).
  Article CAS PubMed Google Scholar
• Apsel, B. et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nature Chem. Biol. 4, 691–699 (2008).
  Article CAS Google Scholar
• Sawyers, C. L. Cancer: mixing cocktails. Nature 449, 993–996 (2007).
  Article CAS PubMed Google Scholar
• Talpaz, M. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354, 2531–2541 (2006).
  Article CAS PubMed Google Scholar
• Kantarjian, H. et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354, 2542–2551 (2006).
  Article PubMed Google Scholar
• Shah, N. P. et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest. 117, 2562–2569 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• O'Hare, T. et al. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc. Natl Acad. Sci. USA 105, 5507–5512 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Gontarewicz, A. et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111, 4355–4364 (2008).
  Article CAS PubMed Google Scholar
• Carter, T. A. et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl Acad. Sci. USA 102, 11011–11016 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• O'Hare, T. et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16, 401–412 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Giles, F. J. et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109, 500–502 (2007).
  Article CAS PubMed Google Scholar
• Weinstein, I. B. et al. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin. Cancer Res. 3, 2696–2702 (1997).
  CAS PubMed Google Scholar
• McDermott, U. et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl Acad. Sci. USA 104, 19936–19941 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358–362 (2006).
  Article CAS PubMed Google Scholar
• Shah, N. P. et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14, 485–493 (2008).
  Article CAS PubMed Google Scholar
• Fan, Q. W. et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9, 341–349 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Haigis, K. M. et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nature Genet. 40, 600–608 (2008).
  Article CAS PubMed Google Scholar
• Fan, Q. W. et al. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res. 67, 7960–7965 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Eichhorn, P. J. et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 68, 9221–9230 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Junttila, T. T. et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15, 429–440 (2009).
  Article CAS PubMed Google Scholar
• Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery. Nature Chem. Biol. 4, 682–690 (2008).
  Article CAS Google Scholar
• Repasky, G. A., Chenette, E. J. & Der, C. J. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol. 14, 639–647 (2004).
  Article CAS PubMed Google Scholar
• Rodriguez-Viciana, P. et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370, 527–532 (1994).
  Article CAS PubMed Google Scholar
• Gupta, S. et al. Binding of ras to phosphoinositide 3-kinase p110α is required for ras-driven tumorigenesis in mice. Cell 129, 957–968 (2007).
  Article CAS PubMed Google Scholar
• Wee, S. et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 69, 4286–93 (2009).
  Article CAS PubMed Google Scholar
• Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nature Med. 14, 1351–1356 (2008).
  Article CAS PubMed Google Scholar
• Normanno, N. et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol. 13, 65–72 (2002).
  Article CAS PubMed Google Scholar
• Moulder, S. L. et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 61, 8887–8895 (2001).
  CAS PubMed Google Scholar
• Bukowski, R. M. et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J. Clin. Oncol. 25, 4536–4541 (2007).
  Article CAS PubMed Google Scholar
• Tonra, J. R. et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin. Cancer Res. 12, 2197–2207 (2006).
  Article CAS PubMed Google Scholar
• Tol, J. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563–572 (2009).
  Article CAS PubMed Google Scholar
• Arteaga, C. L. et al. A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin. Cancer Res. 14, 6277–6283 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Warburton, C. et al. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin. Cancer Res. 10, 2512–2524 (2004).
  Article CAS PubMed Google Scholar
• Normanno, N., Campiglio, M., Perrone, F., De Luca, A. & Menard, S. Is the gefitinib plus trastuzumab combination feasible in breast cancer patients? Ann. Oncol. 16, 1709 (2005).
  Article CAS PubMed Google Scholar
• Motwani, M. et al. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin. Cancer Res. 7, 4209–4219 (2001).
  CAS PubMed Google Scholar
• Shah, M. A. et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin. Cancer Res. 11, 3836–3845 (2005).
  Article CAS PubMed Google Scholar
• Torrance, C. J., Agrawal, V., Vogelstein, B. & Kinzler, K. W. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nature Biotechnol. 19, 940–945 (2001).
  Article CAS Google Scholar
• Manning, B. D. Challenges and opportunities in defining the essential cancer kinome. Sci. Signal 2, 15 (2009).
  Google Scholar
• Goldman, B. For investigational targeted drugs, combination trials pose challenges. J. Natl Cancer Inst. 95, 1744–1746 (2003).
  Article PubMed Google Scholar
• Chen, H. Optimising strategies for clinical development of combinations of targeted agents. Eur. J. Cancer Suppl. 5, 46–52 (2007).
  Google Scholar
• Winslow, R. AstraZeneca, Merck to Test Cancer Drugs in 'Cocktail'. The Wall Street Journal [online], (2009).
• Barry, D. W. & Distlerath, L. M. History and accomplishments of the inter-company collaboration for AIDS drug development. Drug Inf. J. 34, 741–752 (2000).
  Article Google Scholar
• Luo, J. et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835–848 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Scholl, C. et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821–834 (2009).
  Article CAS PubMed Google Scholar
• Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108–112 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Meylan, E. et al. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma. Nature 462, 104–107 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Baldwin, A. et al. Kinase requirements in human cells: II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells. Proc. Natl Acad. Sci. USA 105, 16478–16483 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Grueneberg, D. A. et al. Kinase requirements in human cells: I. Comparing kinase requirements across various cell types. Proc. Natl Acad. Sci. USA 105, 16472–16477 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Morgan-Lappe, S. et al. RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors. Oncogene 25, 1340–1348 (2006).
  Article CAS PubMed Google Scholar
• Luo, Y. et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol. Cancer Ther. 4, 977–986 (2005).
  Article CAS PubMed Google Scholar
• Knight, Z. A. & Shokat, K. M. Chemical genetics: where genetics and pharmacology meet. Cell 128, 425–430 (2007).
  Article CAS PubMed Google Scholar
• Lyons, J. F., Wilhelm, S., Hibner, B. & Bollag, G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer 8, 219–225 (2001).
  Article CAS PubMed Google Scholar
• Hauschild, A. et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 27, 2823–2830 (2009).
  Article CAS PubMed Google Scholar
• Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
  Article CAS PubMed Google Scholar
• Strumberg, D. et al. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int. J. Clin. Pharmacol. Ther. 40, 580–581 (2002).
  Article CAS PubMed Google Scholar
• Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. & Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287–1295 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Gleich, G. J., Leiferman, K. M., Pardanani, A., Tefferi, A. & Butterfield, J. H. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359, 1577–1578 (2002).
  Article CAS PubMed Google Scholar
• Burdine, L. & Kodadek, T. Target identification in chemical genetics: the (often) missing link. Chem. Biol. 11, 593–597 (2004).
  Article CAS PubMed Google Scholar
• Knight, Z. A. & Shokat, K. M. Features of selective kinase inhibitors. Chem. Biol. 12, 621–637 (2005).
  Article CAS PubMed Google Scholar
• Davies, S. P., Reddy, H., Caivano, M. & Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95–105 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Bain, J. et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297–315 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Bamborough, P., Drewry, D., Harper, G., Smith, G. K. & Schneider, K. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J. Med. Chem. 51, 7898–7914 (2008).
  Article CAS PubMed Google Scholar
• Hopkins, A. L., Mason, J. S. & Overington, J. P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 16, 127–136 (2006).
  Article CAS PubMed Google Scholar
• Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnol. 26, 127–132 (2008).
  Article CAS Google Scholar
• Samuels, Y. et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561–73 (2005).
  Article CAS PubMed Google Scholar
• Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002).
  Article CAS PubMed Google Scholar
• Fabian, M. A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnol. 23, 329–336 (2005).
  Article CAS Google Scholar
• Fedorov, O. et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl Acad. Sci. USA 104, 20523–20528 (2007).
  Article CAS PubMed PubMed Central Google Scholar